Bioventus (BVS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 27, 2026
- EPS actual
- $0.22
- EPS estimate
- $0.21
- EPS surprise
- +2.95%
- Revenue surprise
- −1.10%
- Revenue
- $153.2M
- Revenue estimate
- $154.9M
- Reported
- Aug 5, 2026
Bioventus reported Q2 2026 results on August 5, 2026. Earnings per share were $0.22, ahead of the $0.21 estimate by 2.95%. Revenue was $153.2 million, about 1.1% below the $154.9 million consensus. Compared with Q2 2025, EPS rose from $0.21 and revenue rose 3.7% from $147.7 million.
The table shows a recovery from weak results in 2022 and 2023. Annual EPS fell from $0.16 in 2022 to break-even in 2023, with losses in Q4 2022 and Q1 2023, the only losses in the table. It then rose to $0.47 in 2024 and $0.68 in 2025. The first half of 2026 adds up to $0.37, compared with $0.29 a year earlier. Annual revenue grew from $512.4 million in 2023 to about $568 million to $573 million in 2024 and 2025. Q4 2025 set the revenue high here at $157.9 million. Bioventus beat the EPS estimate in 15 of the last 20 quarters, including 13 in a row since Q2 2023.
Bioventus reported its third quarter between November 4 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether the run of EPS beats and year-over-year gains continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.21 | $0.22 | +2.95% | $153.2M | SEC |
| Q1 2026 | May 6, 2026 | $0.07 | $0.15 | +117.71% | $132.1M | SEC |
| Q4 2025 | Mar 5, 2026 | $0.22 | $0.24 | +11.21% | $157.9M | SEC |
| Q3 2025 | Nov 4, 2025 | $0.10 | $0.15 | +43.27% | $138.7M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.16 | $0.21 | +33.67% | $147.7M | SEC |
| Q1 2025 | May 6, 2025 | $0.02 | $0.08 | +225.20% | $123.9M | SEC |
| Q4 2024 | Mar 11, 2025 | $0.08 | $0.15 | +81.60% | $153.6M | SEC |
| Q3 2024 | Nov 5, 2024 | $0.02 | $0.06 | +270.37% | $139.0M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.07 | $0.19 | +182.74% | $151.2M | SEC |
| Q1 2024 | May 7, 2024 | −$0.07 | $0.07 | +204.95% | $129.5M | SEC |
| Q4 2023 | Mar 12, 2024 | $0.02 | $0.07 | +266.49% | $135.4M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.02 | $0.05 | +350.00% | $120.8M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.00 | $0.14 | +4342.42% | $137.1M | SEC |
| Q1 2023 | May 16, 2023 | −$0.15 | −$0.26 | −73.33% | $119.1M | SEC |
| Q4 2022 | Mar 31, 2023 | $0.05 | −$0.06 | −225.00% | $125.8M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.12 | $0.08 | −34.91% | $137.1M | SEC |
| Q2 2022 | Aug 11, 2022 | $0.16 | $0.10 | −35.82% | $140.3M | SEC |
| Q1 2022 | May 10, 2022 | $0.05 | $0.04 | −16.14% | $117.3M | SEC |
| Q4 2021 | Mar 10, 2022 | $0.18 | $0.26 | +47.48% | $130.4M | SEC |
| Q3 2021 | Nov 9, 2021 | $0.14 | $0.25 | +77.94% | $108.9M | SEC |
Quarterly revenue
Frequently asked questions
When did Bioventus (BVS) last report earnings?
Bioventus last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did BVS beat earnings estimates?
Yes. Bioventus reported EPS of $0.22 for Q2 2026 against a $0.21 estimate — a 2.95% beat.
How much revenue did BVS report last quarter?
Bioventus reported $153.2M in revenue for Q2 2026, against a consensus estimate of $154.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.